Synonym
AZD-7687; AZD 7687; AZD7687.
IUPAC/Chemical Name
2-((1s,4s)-4-(4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl)cyclohexyl)acetic acid
InChi Key
YXFNPRHZMOGREC-GASCZTMLSA-N
InChi Code
InChI=1S/C21H25N3O3/c1-12-19(24-20(21(22)27)13(2)23-12)17-9-7-16(8-10-17)15-5-3-14(4-6-15)11-18(25)26/h7-10,14-15H,3-6,11H2,1-2H3,(H2,22,27)(H,25,26)/t14-,15+
SMILES Code
OC(C[C@H]1CC[C@@H](C2=CC=C(C3=C(C)N=C(C(C(N)=O)=N3)C)C=C2)CC1)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
367.45
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Floettmann E, Lees D, Seeliger F, Jones HB. Pharmacological inhibition of
DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia
is restricted to the mouse. Toxicol Pathol. 2015 Apr;43(3):376-83. doi:
10.1177/0192623314545657. Epub 2014 Aug 11. PubMed PMID: 25112279.
2: Denison H, Nilsson C, Löfgren L, Himmelmann A, Mårtensson G, Knutsson M,
Al-Shurbaji A, Tornqvist H, Eriksson JW. Diacylglycerol acyltransferase 1
inhibition with AZD7687 alters lipid handling and hormone secretion in the gut
with intolerable side effects: a randomized clinical trial. Diabetes Obes Metab.
2014 Apr;16(4):334-43. doi: 10.1111/dom.12221. Epub 2013 Oct 31. PubMed PMID:
24118885.
3: Barlind JG, Bauer UA, Birch AM, Birtles S, Buckett LK, Butlin RJ, Davies RD,
Eriksson JW, Hammond CD, Hovland R, Johannesson P, Johansson MJ, Kemmitt PD,
Lindmark BT, Morentin Gutierrez P, Noeske TA, Nordin A, O'Donnell CJ, Petersson
AU, Redzic A, Turnbull AV, Vinblad J. Design and optimization of
pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1)
leading to a clinical candidate dimethylpyrazinecarboxamide
phenylcyclohexylacetic acid (AZD7687). J Med Chem. 2012 Dec 13;55(23):10610-29.
doi: 10.1021/jm301296t. Epub 2012 Nov 21. PubMed PMID: 23116186.
4: Denison H, Nilsson C, Kujacic M, Löfgren L, Karlsson C, Knutsson M, Eriksson
JW. Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a
first-time-in-human single-dose study. Diabetes Obes Metab. 2013
Feb;15(2):136-43. doi: 10.1111/dom.12002. Epub 2012 Sep 30. PubMed PMID:
22950654.